Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 16 Comparasion of the Pfizer and AstraZeneca vaccination centers during the post-vaccination process*

From: Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study

Questions

PZ N = 20 (%)

AZ N = 13 (%)

Total vaccine N = 33 (%)

P-value

1. Patients are being monitored for 15–30 min post-vaccination

 No

6 (30.0)

5 (38.5)

11 (33.3)

0.614

 Yes

14 (70.0)

8 (61.5)

22 (66.7)

2. Counseling and after-care instructions are given at the vaccination site

 No

4 (20.0)

3 (23.1)

7 (21.2)

0.637

 Yes

16 (80.0)

9 (69.2)

25 (75.8)

 Not observed

0 (0.0)

1 (7.70)

1 (3.0)

3. Qualified medical team is available to manage any emergencies or serious adverse event following immunization (AEFI)

 Yes

20 (100.0)

13 (100.0)

33 (100.0)

4. There is a well-equipped designated area at the site for AEFI management

 No

4 (20.0)

2 (15.4)

6 (18.2)

1.0

 Yes

16 (80.0)

11 (84.6)

27 (81.8)

  1. *Statistical tests used included Pearson’s Chi-squared test or Fisher’s exact test